CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.

Therapeutics

Health Care

Biotechnology

CeleCor Therapeutics

CeleCor Therapeutics' headquarters in Del Mar, CA, United States

Robert S. Hillman

Peter Finn

Marijo Gleeson

Chris Granger

John Maraganore

Sooin Kwon

Andrew Weisenfeld

Gilles Montalescot

Jesse Dylan

Michael Levy

Jack Lief

C. Michael Gibson

Martin Gerstel

Rob Stars

The Advisory Team at CeleCor Therapeutics provides expert guidance on the development, clinical trials, and regulatory strategies for the RUC-4 small molecule inhibitor, leveraging their collective experience to optimize its efficacy and safety for treating segment elevated myocardial infarction.

Advisory Team

The Leadership Team at CeleCor Therapeutics is responsible for setting the strategic direction of the company, overseeing the development and commercialization of their novel small molecule inhibitor, and ensuring financial stability. This team also leads collaborations and partnerships, manages corporate governance, and represents the company to stakeholders.

Leadership Team

CeleCor Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

CeleCor Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

Related companies